205 related articles for article (PubMed ID: 2400629)
1. Effect of purified recombinant human erythropoietin on anemia in rats with experimental renal failure induced by five-sixth nephrectomy.
Kawamura A; Higuchi M; Imai N; Kawaguchi T; Ogura Y
Biotherapy; 1990; 2(1):77-85. PubMed ID: 2400629
[TBL] [Abstract][Full Text] [Related]
2. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.
Watson AJ; Gimenez LF; Cotton S; Walser M; Spivak JL
Am J Med; 1990 Oct; 89(4):432-5. PubMed ID: 2220877
[TBL] [Abstract][Full Text] [Related]
3. [Recombinant erythropoietin in autologous blood donation].
von Bormann B; Weidler B; Friedrich M; von Andrian-Werburg H
Anaesthesist; 1991 Jul; 40(7):386-90. PubMed ID: 1928712
[TBL] [Abstract][Full Text] [Related]
4. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen.
Beguin Y; Loo M; R'Zik S; Sautois B; Lejeune F; Rorive G; Fillet G
Blood; 1993 Oct; 82(7):2010-6. PubMed ID: 8400253
[TBL] [Abstract][Full Text] [Related]
5. Anemia and carnitine supplementation in hemodialyzed patients.
Kletzmayr J; Mayer G; Legenstein E; Heinz-Peer G; Leitha T; Hörl WH; Kovarik J
Kidney Int Suppl; 1999 Mar; 69():S93-106. PubMed ID: 10084293
[TBL] [Abstract][Full Text] [Related]
6. Anemia of renal failure. Use of erythropoietin.
Humphries JE
Med Clin North Am; 1992 May; 76(3):711-25. PubMed ID: 1578966
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous recombinant human erythropoietin in children with renal anemia on continuous ambulatory peritoneal dialysis.
Aufricht C; Balzar E; Steger H; Lothaller MA; Frenzel K; Kohlhauser C; Kiss H; Khoss AE; Kernova T
Acta Paediatr; 1993 Nov; 82(11):959-62. PubMed ID: 8111178
[TBL] [Abstract][Full Text] [Related]
8. Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin.
Beguin Y; Loo M; R'Zik S; Sautois B; Lejeune F; Rorive G; Fillet G
Br J Haematol; 1995 Jan; 89(1):17-23. PubMed ID: 7833259
[TBL] [Abstract][Full Text] [Related]
9. Comparison of plasma erythropoietin concentrations and iron status in hemodialyzed patients not requiring and requiring rHuEpo therapy.
Majdan M; Ksiazek A; Kozioł M; Spasiewicz D; Swatowski A; Solski J
Nephron; 1996; 73(3):425-9. PubMed ID: 8832602
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
[TBL] [Abstract][Full Text] [Related]
11. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure.
Hotta T; Ogawa H; Saito A; Ito A
Int J Hematol; 1991 Jun; 54(3):195-200. PubMed ID: 1747454
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB
Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.
Eschbach JW; Abdulhadi MH; Browne JK; Delano BG; Downing MR; Egrie JC; Evans RW; Friedman EA; Graber SE; Haley NR
Ann Intern Med; 1989 Dec; 111(12):992-1000. PubMed ID: 2688507
[TBL] [Abstract][Full Text] [Related]
14. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
[TBL] [Abstract][Full Text] [Related]
15. Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO).
Campos A; Garin EH
Clin Pediatr (Phila); 1992 Feb; 31(2):94-9. PubMed ID: 1544282
[TBL] [Abstract][Full Text] [Related]
16. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients.
Kuriyama S; Hopp L; Yoshida H; Hikita M; Tomonari H; Hashimoto T; Sakai O
Am J Hypertens; 1996 May; 9(5):426-31. PubMed ID: 8735172
[TBL] [Abstract][Full Text] [Related]
17. Effect of erythropoietin on anemia of peritoneally dialyzed anephric rats.
Van Stone JC; Max P
Kidney Int; 1979 Apr; 15(4):370-5. PubMed ID: 513495
[TBL] [Abstract][Full Text] [Related]
18. Effect of hemodialysis and recombinant human erythropoietin on determinants of blood viscosity.
Shand BI; Buttimore AL; Lynn KL; Bailey RR; Robson RA
Ren Fail; 1994; 16(3):407-13. PubMed ID: 8059023
[TBL] [Abstract][Full Text] [Related]
19. Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.
Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):343-54. PubMed ID: 26889660
[TBL] [Abstract][Full Text] [Related]
20. Practical approach to initiation of recombinant human erythropoietin therapy and prevention and management of adverse effects.
Abraham PA
Am J Nephrol; 1990; 10 Suppl 2():7-14. PubMed ID: 2260619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
